Axiom Worldwide's International Medical Advisory Board Steering Committee Issues Consensus Statement Regarding the Axiom Protocols!
2007 NOV 19 -- Axiom Worldwide's International Medical Advisory Board is tasked with providing guidance on Axiom's current and emerging technologies and their application in treating chronic back pain. In addition, the International Medical Advisory Board is further tasked with developing and implementing short and long term clinical trials to validate the safety and efficacy of products utilizing the Axiom Protocols. The goal is to augment the current understanding of how to best treat chronic back pain and determine how the Axiom Protocols should be used in everyday practice for these patients. Retrospective data and the more recent Pilot Study data are very encouraging in favor of the DRX9000(TM). A retrospective review of 94 patients treated on the DRX9000 revealed a reduction in mean low back pain score from 5.99, on a 0 to 10 scale, at initial presentation to 0.87 after the last DRX(TM) treatment. Patients also appeared to have improved function while requiring fewer analgesics after completion of treatment. This study has been accepted for publication in Pain Practice. In a recent prospective Pilot Study of 18 evaluable subjects with a mean ten year history of chronic low back pain, 89% of the patients experienced a clinically and statistically significant reduction of pain greater than 50%. These treatment effects are large when compared to many drug trials and even some types of surgery. In Nov 2006 the Journal of the American Medical Association published the results from the Spine Patient Outcomes Research Trial (SPORT). This National Institutes of Health (NIH) funded study measured surgical versus non-surgical treatment of lumbar disc herniation in patients with radiculopathy for at least six weeks. The authors reported, "Patients in both the surgery and nonoperative treatment groups improved substantially over the first 2 years. Between-group differences in improvements were consistently in favor of surgery for all outcomes and at all time periods but were small..." Compared to this first SPORT study, the effectiveness of the DRX9000, as demonstrated in the Pilot Study, and currently being tested in a multi-center prospective trial of the DRX9000, is noteworthy. Plans for a randomized clinical trial with the DRX9000 will follow this current prospective trial and will help to further define the role of the DRX9000 in the treatment of chronic low back pain. With a safe non-invasive intervention like the DRX9000 and with the known effect of greater than 50% reduction in chronic low back pain following DRX9000 treatment, Axiom Worldwide's International Medical Advisory Board believes the Axiom Protocols and Non-Surgical Spinal Decompression via the DRX9000 should be made routinely available to appropriate patients suffering with chronic low back pain. As a group we look forward to our continued study of the DRX9000 and the Axiom Protocols. Keywords: Analgesia, Back Pain Relief, Chronic Back Pain, Clinical Trial Research, Lower Back Pain, Pain Medicine, Radiculopathy, Axiom Worldwide. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.
|
